Weinstein S H, Schmidt J D
Urology. 1976 Oct;8(4):336-41. doi: 10.1016/0090-4295(76)90486-6.
During the past year 25 patients with advanced transitional cell carcinoma were treated with intravenous doxorubicin hydrochloride (Adriamycin), 60 to 75 mg. per square meter of body surface area, every three weeks. Among the 19 evaluable patients, one partial objective remission lasting five months was observed. All 7 patients with bone pain had symptomatic relief and 12 patients had significant subjective improvement lasting an average of six-and-a-half months. Side effects were minimal and consisted of alopecia, mild leukopenia, and mild stomatitis; no significant cardiotoxicity was observed. Doxorubicin hydrochloride appears to have important antitumor activity in advanced urothelial tumors. Controlled clinical trials with this agent alone and in combined drug regimens are needed.
在过去一年中，25例晚期移行细胞癌患者接受了静脉注射盐酸阿霉素（阿霉素）治疗，每三周一次，剂量为每平方米体表面积60至75毫克。在19例可评估的患者中，观察到1例部分客观缓解，持续5个月。所有7例骨痛患者症状均得到缓解，12例患者主观症状有显著改善，平均持续6个半月。副作用轻微，包括脱发、轻度白细胞减少和轻度口腔炎；未观察到明显的心脏毒性。盐酸阿霉素在晚期尿路上皮肿瘤中似乎具有重要的抗肿瘤活性。需要单独使用该药物以及联合用药方案的对照临床试验。
